Andrew Maslan joined the Institute in 2014 as the Chief Financial Officer. Mr. Maslan leads all aspects of LIBD’s financial management and plays a pivotal role in the organization’s business development efforts. With more than 20 years comprehensive financial and general business experience, including investor relations, capital raising, strategic planning and budgeting, licensing, mergers & acquisitions, financial reporting, and corporate governance, Mr. Maslan provides strategic guidance to the LIBD leadership, and manages all aspects of the organization’s operational financial plans.
Before joining the Lieber Institute, Mr. Maslan served 8 years as CFO for Cytomedix, Inc., a publicly traded medical device/biotechnology company, where he was responsible for the full spectrum of financial and administrative functions, and integrally involved in all capital raising, M&A, licensing, and strategic planning activities. Prior to Cytomedix, Mr. Maslan served as Controller of BioReliance, and previously held various positions of increasing responsibility at GlobeTraders, Inc., Providence Laboratory Associates, and KPMG. Mr. Maslan received his undergraduate degree in Accountancy from Miami University of Ohio and is licensed as a Certified Public Accountant in the state of Maryland.